title: Impact of breast cancer surgery on angiogenesis circulating biomarkers: a prospective longitudinal study.
abstract: BACKGROUND
  Debate about the potential effects that surgery might have on cancer cells dormancy and angiogenesis prompted us to investigate the impact of breast surgery on circulating angiogenesis modulating gene transcripts and proteins.
  
  
  METHODS
  Blood samples from 10 female patients diagnosed with breast cancer and 6 with fibroadenoma were collected before surgery and post-operatively on days 3 and 7 (breast cancer patients only). A set of 84 angiogenesis-associated transcripts were assessed using quantitative PCR arrays, and circulating protein levels (vascular endothelial growth factor A (VEGFA), IL8 and fibroblast growth factor 2 (FGF2) were measured using ELISA in the same samples. The results were investigated against clinicopathological data and patient outcome.
  
  
  RESULTS
  Plasma levels of VEGFA and IL8 after surgery were significantly elevated in the breast cancer group compared to the control group (P = 0.038 and P = 0.021, respectively). In the cohort of breast cancer patients, VEGFA increased on day 3 (P = 0.038) and declined on day 7 (P= 0.017), while IL8 did not change on day 3 but showed a significant decline on day 7 (P = 0.02). FGF2 levels did not change significantly over time. Regarding gene transcripts, we detected upregulation of a significant number of angiogenesis-specific genes in patients with breast cancer versus controls: sphingosine kinase 1(SPHK1), epidermal growth factor (EGF), vascular endothelial growth factor C (VEGFC), neuropilin 1 (NRP1), fibroblast growth factor (FGF1), laminin alpha 5 (LAMA5), collagen type IV alpha 3 (COL4A3), IL8, ephrin B2 (EFNB2), ephrin A3 (EFNA3), tyrosine endothelial kinase (TEK), integrin beta 3 (ITGB3), AKT1, thrombospondin 1 (THBS1), chemokine (C-C motif) ligand 11 (CCL11) and TIMP metallopeptidase inhibitor 3 (TIMP3). Surgery induced an altered expression in several keygenes in breast cancer patients. We identified an upregulation of COL4A3 and downregulation of chemokine (C-X-C motif) ligand 9 (CXCL9), EGF, FGF1, Kinase insert domain receptor (KDR), Placental growth factor (PGF), TIMP3 and VEGFC.
  
  
  CONCLUSIONS
  Breast cancer patients have a different expression profile of circulating angiogenesis biomarkers compared to patients with fibroadenoma. Moreover, mastectomy promotes a transient increase of VEGFA and a shift in the expression patterns of a broad panel of angiogenesis-related circulating gene transcripts.
authors: Department of Surgery, University Hospital of Ioannina, Stavros Niarchos avenue, Ioannina 45500, Greece. georgmd7@gmail.com.
authors: Georgios K
authors: GK
authors: Georgiou
authors: Maria
authors: M
authors: Igglezou
authors: Ioannis
authors: I
authors: Sainis
authors: Katerina
authors: K
authors: Vareli
authors: Haralampos
authors: H
authors: Batsis
authors: Evangelos
authors: E
authors: Briasoulis
authors: Michalis
authors: M
authors: Fatouros
mesh_terms: D000328:Adult; D000368:Aged; D042501:Angiogenic Proteins / Q000235:genetics; D014408:Biomarkers, Tumor / Q000097:blood* / Q000235:genetics; D001943:Breast Neoplasms / Q000097:blood* / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000097:blood* / Q000601:surgery; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D018226:Fibroadenoma / Q000097:blood* / Q000601:surgery; D016222:Fibroblast Growth Factor 2 / Q000097:blood*; D005500:Follow-Up Studies; D006801:Humans; D016209:Interleukin-8 / Q000097:blood*; D008137:Longitudinal Studies; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
chemical_list: D042501:Angiogenic Proteins; D014408:Biomarkers, Tumor; C508606:CXCL8 protein, human; D016209:Interleukin-8; D012333:RNA, Messenger; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2
references: Mol Cancer Res. 2007 Mar;5(3):203-20
references: 17374728
references: Am J Cancer Res. 2011;1(4):460-81
references: 21984966
references: Ann R Coll Surg Engl. 2006 Oct;88(6):525-9
references: 17059709
references: Ann Surg Oncol. 2006 Jan;13(1):125-33
references: 16378159
references: Oncol Rep. 2005 May;13(5):931-6
references: 15809760
references: Br J Cancer. 2002 Feb 1;86(3):490-6
references: 11875720
references: Breast Cancer Res. 2004;6(4):R372-4
references: 15217504
references: Nat Clin Pract Oncol. 2007 Sep;4(9):536-50
references: 17728712
references: Methods. 2001 Dec;25(4):402-8
references: 11846609
references: World J Gastroenterol. 2003 Jun;9(6):1144-55
references: 12800214
references: Semin Cell Dev Biol. 2010 Dec;21(9):951-60
references: 20813200
references: Breast Cancer Res Treat. 2008 Nov;112(1):41-52
references: 18058224
references: Surgery. 2006 Jun;139(6):839-46
references: 16782443
references: Biochem J. 2011 Jul 15;437(2):199-213
references: 21711248
references: Int J Cancer. 1997 Sep 17;72(6):937-41
references: 9378554
references: Genome Biol. 2005;6(2):209
references: 15693956
references: Br J Cancer. 2007 Apr 10;96(7):1092-100
references: 17353919
references: Biochem J. 2000 Jul 15;349(Pt 2):385-402
references: 10880336
references: Clin Cancer Res. 2004 Nov 1;10(21):7157-62
references: 15534087
references: N Engl J Med. 2005 Aug 25;353(8):793-802
references: 16120859
references: Cancer Res. 2012 Feb 1;72(3):726-35
references: 22298596
references: Cancer Res. 2010 Jun 1;70(11):4310-7
references: 20501854
references: Breast Cancer Res Treat. 2005 Sep;93(1):35-40
references: 16184456
references: J Interferon Cytokine Res. 2009 Feb;29(2):83-92
references: 19014340
references: Nat Med. 1995 Feb;1(2):149-53
references: 7585012
references: Nat Med. 1995 Jan;1(1):27-31
references: 7584949
references: Breast Cancer. 2003;10(2):120-8
references: 12736564
references: J Leukoc Biol. 2000 Jul;68(1):1-8
references: 10914483
references: J Clin Oncol. 2005 Mar 10;23(8):1782-90
references: 15755986
references: N Engl J Med. 1971 Nov 18;285(21):1182-6
references: 4938153
references: Ann Oncol. 2008 Nov;19(11):1821-8
references: 18550576
references: Ann Oncol. 2005 Sep;16(9):1449-57
references: 15956037
references: Nat Clin Pract Oncol. 2007 Dec;4(12):699-710
references: 18037874
references: Clin Cancer Res. 2003 Oct 1;9(12):4332-9
references: 14555503
references: Curr Mol Pharmacol. 2010 Jun;3(2):53-65
references: 20302564
references: Crit Rev Oncol Hematol. 2000 Jun;34(3):185-94
references: 10838264